Priority review for BMS’ Opdivo in liver cancer

US regulators will undertake a speedy review of Bristol-Myers Squibb’s application to expand use of its immunotherapy Opdivo to include to include certain patients with liver cancer.

Read on PharmaTimes

Pfizer’s Epogen/Procrit biosimilar wins US backing

Pfizer’s biosimilar of Amgen’s epoetin alfa (Epogen/Procrit) has won backing in the US for approval across all proposed indications.

Read on PharmaTimes

UK researchers find evidence of ‘nocebo’ effect for statins

Patients report more side effects when they know they are taking a statin than when don’t, according to findings of a recent study led by researchers at Imperial College London, funded by Pfizer, and published in The Lancet.

Read on PharmaTimes

Merck buys experimental tau antibody from Teijin

Merck & Co has bought itself an exclusive global licence from Teijin Pharma to develop, manufacture and commercialise an investigational preclinical antibody candidate targeting a protein called tau.

Read on PharmaTimes

EU regulators widen approval for Zebinix

The European Medicines Agency has cleared use of Bial and Eisai’s sodium channel blocker Zebinix for use as a once-daily monotherapy to treat adults with newly-diagnosed partial-onset epilepsy, widening its treatment scope in the region.

Read on PharmaTimes

1 2 3

Top of page

Industry News

US regulators will undertake a speedy review of Bristol-Myers Squibb’s application to expand use of its immunotherapy Opdivo to include...
Read More >

More Stories

News

Recent launch of several new categories of compound which include the spirocyclic β-Lactams designed...
Read More >

More Stories

Latest Tweets

Follow Us